Balloon Angioplasty Versus Xpert Stent in CLI Patients XXS Study (XXS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00546845
Recruitment Status : Unknown
Verified October 2007 by University Hospital Tuebingen. Recruitment status was: Recruiting
This study is an investigator-initiated study. The study will be performed as a prospective, randomized, controlled multi-center trial to evaluate the safety and efficiency of Xpert stents compared to PTA in patients with chronic distal artery occlusions or stenosis undergoing catheter revascularization. Patients will be eligible for randomization if they are over 18 years old, if they undergo percutaneous catheter revascularization of an artery below the knee stenosis/occlusion that is less than 15 centimeters in length. Up to two vessels may be treated in this study. All lesions greater than 50% in the below the knee artery region have to be treated either with PTA or stenting according to the randomization.
Condition or disease
Cronic Limb IshemiaIntervention
Device: Balloon angioplastyDevice: Use of self-expanding Expert stent
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
1. Age between 18 and 95 years. 2. Subject or subject's legal representative have been informed of the nature of the study, and have signed the patient informed consent form. Patient is willing to take part in the follow-up protocol of the XXS study.
3. Rutherford stage 4 and 5 Anatomical:
Additional lesions inflow lesions might be successfully treated before randomization and treatment of the target lesion. The inflow lesions which were treated before randomization should only be classified TASC A or B. (TASC= Trans Atlantic Intersociety Conference)
Target vessel with documented run-off to the foot distally of the index lesion with patent plantar arteries
Reference vessel diameter of the target lesion should be ≥ 2 and ≤ 5 mm.
Maximum treated length in the target vessel is 15 cm (might also be divided up into multiple segments with up to 3 different lesions being treated).
Maximum of treated vessels per leg below the knee: 2 (all treated vessels should be treated within the randomization to the study group [PTA or stenting]).
Minimum distance target lesion to talus is 5 cm.
Life expectancy due to a non-atheroslerotic disease less than 12 months.
Previous bypass surgery < 30 days prior to the study procedure.
Known allergies or sensitivities to heparin, contrast media, aspirin, clopidogrel, and nitinol which cannot be treated with antihistamines.
eGFR less than 29 mL/min/1.73m2 (K-DOQI Class 4 and 5) in patients which are not currently treated with dialysis (equivalent to a serum creatinine level of 2.4 mg/dL in a 70 year old male patient)
Subject with breast feeding plans, or child bearing potential with no birth control.
Subjects enrolled in another study concerning the index vessel(s) within 3 months prior to the study procedure.
Untreatable bleeding diatheses.
Patients who have an indication of being treated with coumadin after the intervention.
Inability to ambulate
Patients with age <18 years and patients who are not able to sign the informed consent form
Inflow is obstructed and cannot be successfully treated prior to randomization and treatment of below the knee arteries.
Acute thrombus present in the target limb.
Previously implanted stent in the target vessel(s).
Aneurysms in the index leg.
Index vessel with no documented run-up to the foot (please also see inclusion criteria, anatomical).